Details of the Drug

General Information of Drug (ID: DMMYPWO)

Drug Name
Alefacept
Synonyms Amevive (TN)
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1]
Therapeutic Class
Analgesics
Sequence
>heavy chain
CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVS
GSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEH
YNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIP
SSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCP
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPQVKFNWYVDGVQVHNAKTK
PREQQYNSTYRVVSVLTVLHQNWLDGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQK
DKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYV
LESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMEND
LPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKC
DRKPDRTNSN
ADMET Property
Bioavailability
The bioavailability of drug is 63% []
Half-life
The concentration or amount of drug in body reduced by one-half in 270 hours [2]
Cross-matching ID
DrugBank ID
DB00092
TTD ID
D09ZSO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Surface glycoprotein LFA-3 (CD58) TT5KSBY LFA3_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Alefacept
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Buprenorphine DMPRI8G Moderate Altered metabolism of Alefacept due to Buprenorphine alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [4]
Oxycodone DMXLKHV Moderate Altered metabolism of Alefacept due to Oxycodone alters the formation of CYP450 enzymes. Pain [MG30-MG3Z] [4]
Coadministration of a Drug Treating the Disease Different from Alefacept (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Altered metabolism of Alefacept due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [4]
Nifedipine DMSVOZT Moderate Altered metabolism of Alefacept due to Nifedipine alters the formation of CYP450 enzymes. Angina pectoris [BA40] [4]
Alprazolam DMC7XDN Moderate Altered metabolism of Alefacept due to Alprazolam alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [4]
Methylphenobarbital DMDSWAG Moderate Altered metabolism of Alefacept due to Methylphenobarbital alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [5]
Clobazam - Lundbeck DMW1OQ0 Moderate Altered metabolism of Alefacept due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. Anxiety disorder [6B00-6B0Z] [4]
Aminophylline DML2NIB Moderate Altered metabolism of Alefacept due to Aminophylline alters the formation of CYP450 enzymes. Asthma [CA23] [4]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Alefacept and Roflumilast. Asthma [CA23] [4]
Atorvastatin DMF28YC Moderate Altered metabolism of Alefacept due to Atorvastatin alters the formation of CYP450 enzymes. Cardiovascular disease [BA00-BE2Z] [4]
Drospirenone DM1A9W3 Moderate Altered metabolism of Alefacept due to Drospirenone alters the formation of CYP450 enzymes. Contraceptive management [QA21] [4]
Levonorgestrel DM1DP7T Moderate Altered metabolism of Alefacept due to Levonorgestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [4]
Desogestrel DM27U4Y Moderate Altered metabolism of Alefacept due to Desogestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [5]
Mestranol DMG3F94 Moderate Altered metabolism of Alefacept due to Mestranol alters the formation of CYP450 enzymes. Contraceptive management [QA21] [5]
Etonogestrel DMKA8J4 Moderate Altered metabolism of Alefacept due to Etonogestrel alters the formation of CYP450 enzymes. Contraceptive management [QA21] [4]
Norgestimate DMYP4XC Moderate Altered metabolism of Alefacept due to Norgestimate alters the formation of CYP450 enzymes. Contraceptive management [QA21] [5]
Lidocaine DML4ZOT Moderate Altered metabolism of Alefacept due to Lidocaine alters the formation of CYP450 enzymes. Corneal disease [9A76-9A78] [4]
Nimodipine DMQ0RKZ Moderate Altered metabolism of Alefacept due to Nimodipine alters the formation of CYP450 enzymes. Coronary vasospastic disease [BA85] [4]
Oxtriphylline DMLHSE3 Moderate Altered metabolism of Alefacept due to Oxtriphylline alters the formation of CYP450 enzymes. Cough [MD12] [4]
Methadone DMTW6IU Moderate Altered metabolism of Alefacept due to Methadone alters the formation of CYP450 enzymes. Cough [MD12] [4]
Rivaroxaban DMQMBZ1 Moderate Altered metabolism of Alefacept due to Rivaroxaban alters the formation of CYP450 enzymes. Deep vein thrombosis [BD71] [4]
PMID28870136-Compound-48 DMPIM9L Moderate Altered metabolism of Alefacept due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. Discovery agent [N.A.] [4]
Oestradiol valerate and dienogest DMZK0FQ Moderate Altered metabolism of Alefacept due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. Endometriosis [GA10] [5]
Primidone DM0WX6I Moderate Altered metabolism of Alefacept due to Primidone alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Mephenytoin DM5UGDK Moderate Altered metabolism of Alefacept due to Mephenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Ethosuximide DMDZ9LT Moderate Altered metabolism of Alefacept due to Ethosuximide alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Phenytoin DMNOKBV Moderate Altered metabolism of Alefacept due to Phenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Fosphenytoin DMOX3LB Moderate Altered metabolism of Alefacept due to Fosphenytoin alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Clonazepam DMTO13J Moderate Altered metabolism of Alefacept due to Clonazepam alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Phenobarbital DMXZOCG Moderate Altered metabolism of Alefacept due to Phenobarbital alters the formation of CYP450 enzymes. Epilepsy/seizure [8A61-8A6Z] [4]
Nicardipine DMCDYW7 Moderate Altered metabolism of Alefacept due to Nicardipine alters the formation of CYP450 enzymes. Essential hypertension [BA00] [4]
Simvastatin DM30SGU Moderate Altered metabolism of Alefacept due to Simvastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [4]
Lovastatin DM9OZWQ Moderate Altered metabolism of Alefacept due to Lovastatin alters the formation of CYP450 enzymes. Hyper-lipoproteinaemia [5C80] [4]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Alefacept and Teriflunomide. Hyper-lipoproteinaemia [5C80] [6]
Nisoldipine DM7ISKJ Moderate Altered metabolism of Alefacept due to Nisoldipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [4]
Levamlodipine DM92S6N Moderate Altered metabolism of Alefacept due to Levamlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [4]
Isradipine DMA5XGH Moderate Altered metabolism of Alefacept due to Isradipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [4]
Amlodipine DMBDAZV Moderate Altered metabolism of Alefacept due to Amlodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [4]
Felodipine DMOSW35 Moderate Altered metabolism of Alefacept due to Felodipine alters the formation of CYP450 enzymes. Hypertension [BA00-BA04] [4]
Triazolam DMETYK5 Moderate Altered metabolism of Alefacept due to Triazolam alters the formation of CYP450 enzymes. Insomnia [7A00-7A0Z] [4]
Lurbinectedin DMEFRTZ Moderate Additive myelosuppressive effects by the combination of Alefacept and Lurbinectedin. Lung cancer [2C25] [4]
Cladribine DM3JDRP Major Additive immunosuppressive effects by the combination of Alefacept and Cladribine. Mature B-cell leukaemia [2A82] [4]
Vincristine DMINOX3 Moderate Additive immunosuppressive effects by the combination of Alefacept and Vincristine. Mature B-cell lymphoma [2A85] [4]
Ethinyl estradiol DMODJ40 Moderate Altered metabolism of Alefacept due to Ethinyl estradiol alters the formation of CYP450 enzymes. Menopausal disorder [GA30] [5]
Midazolam DMXOELT Moderate Altered metabolism of Alefacept due to Midazolam alters the formation of CYP450 enzymes. Mood/affect symptom [MB24] [4]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Alefacept and Siponimod. Multiple sclerosis [8A40] [7]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Alefacept and Fingolimod. Multiple sclerosis [8A40] [8]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Alefacept and Ozanimod. Multiple sclerosis [8A40] [4]
Efalizumab DMCKL5V Moderate Additive immunosuppressive effects by the combination of Alefacept and Efalizumab. Psoriasis [EA90] [9]
Everolimus DM8X2EH Moderate Additive immunosuppressive effects by the combination of Alefacept and Everolimus. Renal cell carcinoma [2C90] [4]
Temsirolimus DMS104F Moderate Additive myelosuppressive effects by the combination of Alefacept and Temsirolimus. Renal cell carcinoma [2C90] [4]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Alefacept and Leflunomide. Rheumatoid arthritis [FA20] [6]
Fentanyl DM8WAHT Moderate Altered metabolism of Alefacept due to Fentanyl alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [4]
Sufentanil DMU7YEL Moderate Altered metabolism of Alefacept due to Sufentanil alters the formation of CYP450 enzymes. Sensation disturbance [MB40] [4]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Alefacept when combined with Anthrax vaccine. Sepsis [1G40-1G41] [10]
Vinblastine DM5TVS3 Moderate Additive myelosuppressive effects by the combination of Alefacept and Vinblastine. Solid tumour/cancer [2A00-2F9Z] [4]
Norethindrone DMTY169 Moderate Altered metabolism of Alefacept due to Norethindrone alters the formation of CYP450 enzymes. Solid tumour/cancer [2A00-2F9Z] [5]
Vinorelbine DMVXFYE Moderate Additive myelosuppressive effects by the combination of Alefacept and Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [4]
Warfarin DMJYCVW Moderate Altered metabolism of Alefacept due to Warfarin alters the formation of CYP450 enzymes. Supraventricular tachyarrhythmia [BC81] [4]
Dicumarol DMFQCB1 Moderate Altered metabolism of Alefacept due to Dicumarol alters the formation of CYP450 enzymes. Thrombosis [DB61-GB90] [5]
Sirolimus DMGW1ID Moderate Additive myelosuppressive effects by the combination of Alefacept and Sirolimus. Transplant rejection [NE84] [4]
Tacrolimus DMZ7XNQ Moderate Additive myelosuppressive effects by the combination of Alefacept and Tacrolimus. Transplant rejection [NE84] [4]
Disopyramide DM5SYZP Moderate Altered metabolism of Alefacept due to Disopyramide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
Mexiletine DMCTE9R Moderate Altered metabolism of Alefacept due to Mexiletine alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
Procainamide DMNMXR8 Moderate Altered metabolism of Alefacept due to Procainamide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
Propafenone DMPIBJK Moderate Altered metabolism of Alefacept due to Propafenone alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
Flecainide DMSQDLE Moderate Altered metabolism of Alefacept due to Flecainide alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
Amiodarone DMUTEX3 Moderate Altered metabolism of Alefacept due to Amiodarone alters the formation of CYP450 enzymes. Ventricular tachyarrhythmia [BC71] [4]
⏷ Show the Full List of 66 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6787).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
6 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
9 Product Information. Raptiva (efalizumab). Genentech, South San Francisco, CA.
10 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]